| Summary: | 碩士 === 國立臺灣大學 === 臨床醫學研究所 === 91 === Abstract
In a randomized controlled study, 137 male children (211 testes units) with 74(1.0 — 12.0 years old, median 4.7 years old) bilateral and 63 (10 months old — 14.0 years old, median 4.4 years old) with unilateral cryptorchidism were allocated to treatment with either human chorionic gonadotrophin (im)(G1), gonadotrophin releasing hormone analogue (intranasally)(G2) or two combined hormone therapy(G3). In individuals with the bilateral or unilateral undescending testes treatment with human chorionic gonadotrophin, gonadotrophin releasing hormone analogue or two combined hormone therapy resulted in higher complete descent ratio than those(G0) with controlled treatment by close observation(bilateral 49.9% to 8.5%;unilateral 44.8% to 12.5%). Success rate in bilateral cases, result of treatment with luteinizing hormone releasing hormone analogue (Buserelin) was significantly better than those obtained with human chorionic gonadotrophin therapy (72.2% to 44.4%)；In unilateral cryptorchidism cases, treatment with GnRH, Buserelin, resulted in complete descent in 44.4% of testes units, better than those with HCG, 40.0%.
Linear and logistic regression analysis of the results obtained by treatment of bilateral disease showed that all treatments were more successful the younger the age of the male children. The data indicated that bilateral and unilateral cryptorchidism respond differently to hormonal treatment. We suggest that luteinizing hormone releasing hormone analogue (Buserelin) should be the first choice of treatment for prepubertal boys, especially younger than three years old.
|
|---|
